{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:08:25Z","timestamp":1794348505581,"version":"4.9.0"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2024,7,31]],"date-time":"2024-07-31T00:00:00Z","timestamp":1722384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Anti-synthetase syndrome (ASS) is a chronic autoimmune condition, with interstitial lung disease (ILD) being a key feature. This systematic literature review (SLR; CRD42023416414) aimed to summarize treatments and outcomes of ILD associated with ASS (ASS-ILD).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Databases were searched for articles discussing ASS-ILD management and outcomes, published 1946\u2013September 2023. Screening and data extraction were performed by two reviewers. Meta-analysis, using a random effects model, and paired t-tests were undertaken where appropriate to evaluate post-treatment-change in pulmonary function tests.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Ten articles were included, comprising 514 patients: 67.8% female, mean age 52.4\u2009years (s.d. 4.6). Baseline high-resolution CT was documented in 447 patients (86.9%); the most common pattern was non-specific interstitial pneumonia (n\u2009=\u2009220; 49.2%). The most common myositis-associated autoantibody was anti-Jo1 (48%), with 27.8% having associated anti-Ro52 antibodies. Pooled estimate, after meta-analysis, for baseline forced vital capacity (FVC) was 60.8% predicted (s.e. 2.1) and for diffusion capacity of lungs for carbon monoxide (DLco) was 49.8% (s.e. 3.5). After 1\u2009year, pooled improvement in FVC was 14.1% from baseline (s.e. 3.1) and in DLco was 15.1% (s.e. 2.8). Paired t-test demonstrated significant overall improvement in FVC (P\u2009=\u20090.007) and DLco (P\u2009=\u20090.002). Patients receiving rituximab had 12.2% improvement in FVC and 2.9% increase in DLco at 1\u2009year; for patients receiving CYC, there was 17% improvement and 6.3% increase, respectively. Twenty-eight deaths were reported.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Our SLR, the first to summarize management and outcomes of ASS-ILD, found no conclusive difference between effectiveness of treatments. More robust trials are required to reduce morbidity and mortality resulting from ASS-ILD.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keae403","type":"journal-article","created":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T03:17:06Z","timestamp":1722482226000},"page":"45-55","source":"Crossref","is-referenced-by-count":18,"title":["Management and outcomes of interstitial lung disease associated with anti-synthetase syndrome: a systematic literature review"],"prefix":"10.1093","volume":"64","author":[{"given":"Koushan","family":"Kouranloo","sequence":"first","affiliation":[{"name":"Department of Rheumatology, University Hospital Lewisham , London,","place":["UK"]},{"name":"School of Medicine, Cedar House, University of Liverpool , Liverpool,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6858-4338","authenticated-orcid":false,"given":"Mrinalini","family":"Dey","sequence":"additional","affiliation":[{"name":"Centre for Rheumatic Diseases, Kings\u2019 College London, Weston Education Centre , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Elwell","sequence":"additional","affiliation":[{"name":"British Medical Association library, BMA House , London,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Yioe","sequence":"additional","affiliation":[{"name":"Liverpool Regional Interstitial Lung Disease Service, Aintree Chest Centre, Aintree Hospital, Liverpool University NHS Foundation Trust , Liverpool,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa G","family":"Spencer","sequence":"additional","affiliation":[{"name":"Liverpool Regional Interstitial Lung Disease Service, Aintree Chest Centre, Aintree Hospital, Liverpool University NHS Foundation Trust , Liverpool,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline V","family":"Cotton","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Liverpool University NHS Foundation Trust , Liverpool,","place":["UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,31]]},"reference":[{"key":"2025010608402709500_keae403-B1","doi-asserted-by":"crossref","first-page":"609595","DOI":"10.3389\/fmed.2020.609595","article-title":"Antisynthetase syndrome-associated interstitial lung disease: monitoring of immunosuppressive treatment effects by chest computed tomography","volume":"7","author":"Korsten","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"2025010608402709500_keae403-B2","article-title":"Clinicoserological features of antisynthetase syndrome (ASyS)-associated interstitial lung disease presenting to respiratory services: comparison with idiopathic pulmonary fibrosis and ASyS diagnosed in rheumatology services","volume":"8","author":"Barratt","year":"2021","journal-title":"BMJ Open Respir Res"},{"key":"2025010608402709500_keae403-B3","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"2025010608402709500_keae403-B4","author":"Kouranloo"},{"key":"2025010608402709500_keae403-B5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s10067-022-06424-4","article-title":"An observational study of clinical recurrence in patients with interstitial lung disease related to the antisynthetase syndrome","volume":"42","author":"Chen","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025010608402709500_keae403-B6","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12890-021-01399-5","article-title":"Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China","volume":"21","author":"Zhan","year":"2021","journal-title":"BMC Pulm Med"},{"key":"2025010608402709500_keae403-B7","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.3899\/jrheum.190505","article-title":"Rituximab and cyclophosphamide in antisynthetase syndrome-related interstitial lung disease: an observational retrospective study","volume":"47","author":"Langlois","year":"2020","journal-title":"J Rheumatol"},{"key":"2025010608402709500_keae403-B8","doi-asserted-by":"crossref","first-page":"415","DOI":"10.3899\/jrheum.181141","article-title":"Evolution of pulmonary function in a cohort of patients with interstitial lung disease and positive for antisynthetase antibodies","volume":"47","author":"Gonz\u00e1lez-P\u00e9rez","year":"2020","journal-title":"J Rheumatol"},{"key":"2025010608402709500_keae403-B9","doi-asserted-by":"crossref","first-page":"1583516","DOI":"10.1080\/20018525.2019.1583516","article-title":"Clinical characteristics and outcome in patients with antisynthetase syndrome associated interstitial lung disease: a retrospective cohort study","volume":"6","author":"Jensen","year":"2019","journal-title":"Eur Clin Respir J"},{"key":"2025010608402709500_keae403-B10","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.rmed.2019.05.012","article-title":"Long-term treatment with human immunoglobulin for antisynthetase syndrome-associated interstitial lung disease","volume":"154","author":"Huapaya","year":"2019","journal-title":"Respir Med"},{"key":"2025010608402709500_keae403-B11","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/rheumatology\/kev004","article-title":"Long-term experience with rituximab in anti-synthetase syndrome-related interstitial lung disease","volume":"54","author":"Andersson","year":"2015","journal-title":"Rheumatology (Oxford)"},{"key":"2025010608402709500_keae403-B12","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/rheumatology\/kep157","article-title":"Rituximab treatment of the anti-synthetase syndrome\u2014a retrospective case series","volume":"48","author":"Sem","year":"2009","journal-title":"Rheumatology"},{"key":"2025010608402709500_keae403-B13","first-page":"181","article-title":"Effects of rituximab in connective tissue disorders related interstitial lung disease","volume":"34(Suppl 100)","author":"Lepri","year":"2016","journal-title":"Clin Exp Rheumatol"},{"key":"2025010608402709500_keae403-B14","first-page":"436","article-title":"Calcineurin inhibitors in a cohort of patients with antisynthetase-associated interstitial lung disease\u2014PubMed","volume":"31","author":"Labirua-Iturburu","year":"2013","journal-title":"Clin Exp Rheumatol"},{"key":"2025010608402709500_keae403-B15","author":"The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute"},{"key":"2025010608402709500_keae403-B16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1186\/s13063-017-2016-2","article-title":"Rituximab versus cyclophosphamide for the treatment of connective tissue diseaseassociated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial","volume":"18","author":"Saunders","year":"2017","journal-title":"Trials"},{"key":"2025010608402709500_keae403-B17","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1002\/art.21240","article-title":"Treatment of antisynthetase-associated interstitial lung disease with tacrolimus","volume":"52","author":"Wilkes","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2025010608402709500_keae403-B18","first-page":"2484","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study","volume":"60(Suppl 66)","author":"Lettieri","year":"2022","journal-title":"Eur Respir J"},{"key":"2025010608402709500_keae403-B19","doi-asserted-by":"crossref","first-page":"ii10","DOI":"10.1093\/rap\/rkab054","article-title":"Clinical profile and treatment outcomes in antisynthetase syndrome: a tertiary centre experience","volume":"5","author":"Sreevilasan","year":"2021","journal-title":"Rheumatol Adv Pract"},{"key":"2025010608402709500_keae403-B20","doi-asserted-by":"crossref","first-page":"e1144","DOI":"10.1097\/MD.0000000000001144","article-title":"Clinical Spectrum Time Course in Anti Jo-1 Positive Antisynthetase Syndrome: results From an International Retrospective Multicenter Study","volume":"94","author":"Cavagna","year":"2015","journal-title":"Medicine"},{"key":"2025010608402709500_keae403-B21","doi-asserted-by":"crossref","first-page":"103536","DOI":"10.1016\/j.autrev.2024.103536","article-title":"Prevalence of anti-Ro52-kDa\/SSA (TRIM21) antibodies and associated clinical phenotype in systemic sclerosis: data from a French cohort, a systematic review and meta-analysis","volume":"23","author":"Martel","year":"2024","journal-title":"Autoimmun Rev"},{"key":"2025010608402709500_keae403-B22","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2021.04.020","article-title":"Clinical significance of anti-Ro52 (TRIM21) antibodies in adult patients with connective tissue diseases","volume":"91","author":"Decker","year":"2021","journal-title":"Eur J Intern Med"},{"key":"2025010608402709500_keae403-B23","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.3899\/jrheum.150844","article-title":"Rituximab in the treatment of Jo1 antibody-associated antisynthetase syndrome: anti-Ro52 positivity as a marker for severity and treatment response","volume":"43","author":"Bauhammer","year":"2016","journal-title":"J Rheumatol"},{"key":"2025010608402709500_keae403-B24","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1093\/rheumatology\/keaa786","article-title":"Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease","volume":"60","author":"Xu","year":"2021","journal-title":"Rheumatology"},{"key":"2025010608402709500_keae403-B25","doi-asserted-by":"crossref","first-page":"27","DOI":"10.55563\/clinexprheumatol\/bjb2gf","article-title":"Anti-Ro52 antibodies positivity in antisynthetase syndrome: a single centre cohort study","volume":"40(Suppl 134)","author":"Bozzalla-Cassione","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2025010608402709500_keae403-B26","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11604-020-01030-3","article-title":"Interstitial lung disease in patients with antisynthetase syndrome: a retrospective case series study","volume":"39","author":"Baratella","year":"2021","journal-title":"Jpn J Radiol"},{"key":"2025010608402709500_keae403-B27","doi-asserted-by":"crossref","first-page":"959653","DOI":"10.3389\/fmed.2022.959653","article-title":"A multidisciplinary approach to the diagnosis of antisynthetase syndrome","volume":"9","author":"Wells","year":"2022","journal-title":"Front Med (Lausanne)"},{"key":"2025010608402709500_keae403-B28","doi-asserted-by":"crossref","first-page":"A193","DOI":"10.1136\/thoraxjnl-2014-206260.392","article-title":"P274 anti-synthetase syndrome: validity of ANA as a screening tool\u2014the Oxford ILD service experience","volume":"69","author":"Nicholson","year":"2014","journal-title":"Thorax"},{"key":"2025010608402709500_keae403-B29","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/acr.21895","article-title":"Interstitial lung disease in anti-Jo-1 patients with antisynthetase syndrome","volume":"65","author":"Marie","year":"2013","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025010608402709500_keae403-B30","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1183\/09031936.00014707","article-title":"Acute respiratory distress syndrome secondary to antisynthetase syndrome is reversible with tacrolimus","volume":"31","author":"Guglielmi","year":"2008","journal-title":"Eur Respir J"},{"key":"2025010608402709500_keae403-B31","first-page":"73","article-title":"Nonspecific interstitial pneumonia: radiologic, clinical, and pathologic considerations","volume-title":"RadioGraphics","author":"Kligerman","year":"2009"},{"key":"2025010608402709500_keae403-B32","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3899\/jrheum.151067","article-title":"Pulmonary involvement in the antisynthetase syndrome: a comparative cross-sectional study","volume":"43","author":"Andersson","year":"2016","journal-title":"J Rheumatol"},{"key":"2025010608402709500_keae403-B33","doi-asserted-by":"crossref","first-page":"1106560","DOI":"10.3389\/fmed.2023.1106560","article-title":"Prognostication of progressive pulmonary fibrosis in connective tissue disease-associated interstitial lung diseases: a cohort study","volume":"10","author":"Chiu","year":"2023","journal-title":"Front Med (Lausanne)"},{"key":"2025010608402709500_keae403-B34","doi-asserted-by":"crossref","first-page":"2101396","DOI":"10.1183\/13993003.01396-2021","article-title":"Lung function trajectory in progressive fibrosing interstitial lung disease","volume":"59","author":"Oldham","year":"2022","journal-title":"Eur Respir J"},{"key":"2025010608402709500_keae403-B35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1378\/chest.13-2626","article-title":"Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review","volume":"146","author":"Winstone","year":"2014","journal-title":"Chest"},{"key":"2025010608402709500_keae403-B36","doi-asserted-by":"crossref","first-page":"1600016","DOI":"10.1183\/13993003.00016-2016","article-title":"2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung","volume":"49","author":"Graham","year":"2017","journal-title":"Eur Respir J"},{"key":"2025010608402709500_keae403-B37","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1183\/09031936.00156312","article-title":"Pulmonary hypertension in antisynthetase syndrome: prevalence, aetiology and survival","volume":"42","author":"Hervier","year":"2013","journal-title":"Eur. Respir J"},{"key":"2025010608402709500_keae403-B38","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S2213-2600(22)00359-9","article-title":"Rituximab versus intravenous cyclophosphamide in patients with connective tissue disease-associated interstitial lung disease in the UK (RECITAL): a double-blind, double-dummy, randomised, controlled, phase 2b trial","volume":"11","author":"Maher","year":"2023","journal-title":"Lancet Respir Med"},{"key":"2025010608402709500_keae403-B39","doi-asserted-by":"crossref","first-page":"101503","DOI":"10.1016\/j.berh.2020.101503","article-title":"Clinical manifestations and treatment of antisynthetase syndrome","volume":"34","author":"Marco","year":"2020","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"2025010608402709500_keae403-B40","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11926-012-0246-6","article-title":"Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment","volume":"14","author":"Mimori","year":"2012","journal-title":"Curr Rheumatol Rep"},{"key":"2025010608402709500_keae403-B41","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1093\/rheumatology\/kex021","article-title":"A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies","volume":"56","author":"Pinal-Fernandez","year":"2017","journal-title":"Rheumatology"},{"key":"2025010608402709500_keae403-B42","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1136\/ard-2022-223335","article-title":"2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases","volume":"82","author":"Fragoulis","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2025010608402709500_keae403-B43","doi-asserted-by":"crossref","first-page":"5349","DOI":"10.1007\/s00330-019-06152-5","article-title":"Prognostic factors of interstitial lung disease progression at sequential HRCT in anti-synthetase syndrome","volume":"29","author":"Liu","year":"2019","journal-title":"Eur Radiol"},{"key":"2025010608402709500_keae403-B44","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1007\/s10067-023-06570-3","article-title":"Prediction of progressive pulmonary fibrosis in patients with anti-synthetase syndrome-associated interstitial lung disease","volume":"42","author":"Fu","year":"2023","journal-title":"Clin Rheumatol"},{"key":"2025010608402709500_keae403-B45","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"New England Journal of Medicine"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keae403\/58811977\/keae403.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/1\/45\/58811977\/keae403.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/1\/45\/58811977\/keae403.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T08:41:36Z","timestamp":1736152896000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/1\/45\/7724839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,31]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,7,31]]},"published-print":{"date-parts":[[2025,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keae403","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,1]]},"published":{"date-parts":[[2024,7,31]]}}}